Quality and safety of Telemedicine in acute ischemic stroke: Early experience in Taiwan

J Formos Med Assoc. 2022 Jan;121(1 Pt 2):314-318. doi: 10.1016/j.jfma.2021.04.024. Epub 2021 May 13.

Abstract

Background: Telemedicine helps to provide the safe management of stroke patients in the emergency department (ED) and has been used worldwide. However, we had limited experience of telestroke in Taiwan. We aimed to identify the quality of telestroke and compare it with the original face-to-face consultation model.

Methods: Among 178 consecutive acute ischemic stroke patients treated with intravenous tissue plasminogen activator (IVtPA) from January 1, 2018, to December 31, 2019, we compared two different consultation methods: face-to-face consultation and telestroke consultation. We collected data on demographics, the National Institutes of Health Stroke Scale (NIHSS) scores, Modified Rankin Scale (mRS) scores, time measurements (onset-to-arrival time, onset-to-telestroke activation time, and time of IVtPA administration (Door-to-Needle; DTN)).

Results: The mean age to receive a telestroke consultation was 66.6 years, 36% were female, and the median NIHSS score was 9. The median time from patient arrival to telestroke consult activation was 40 min, and the median DTN time was 11 min longer than for face-to-face consults (62 min versus 51 min, p = .01). Telestroke consultation, similar to a face-to-face consultation, resulted in safe IVtPA eligibility assessments and administration with post-thrombolysis ICH in 4% overall (4% telestroke, 3% face-to-face consultation; p = .851). The 90-day outcomes were not different for mRS score, dichotomized 0-2 (60% telestroke 59% face-to-face consultation; p = .961), or for mortality (16% telestroke, 9% face-to-face consultation; p = .292).

Conclusion: In the ED, consultation via the telestroke program provides equal quality to the original face-to-face consultation model to manage ischemic stroke.

Keywords: Ischemic stroke; Telemedicine; Telestroke; Thrombolytics.

MeSH terms

  • Brain Ischemia* / drug therapy
  • Female
  • Humans
  • Ischemic Stroke* / drug therapy
  • Taiwan
  • Telemedicine*
  • Tissue Plasminogen Activator / therapeutic use
  • United States

Substances

  • Tissue Plasminogen Activator